INDICATION
● Osteoarthritis.
● Rheumatoid arthritis.
● Ankylosing spondylitis.
DOSAGE AND ADMINISTRATION
For Adults:
Osteoarthritis: 7.5 mg/day. If necessary, in the absence of improvement, the
dose may be increased to 15 mg/day.
Rheumatoid arthritis: 15 mg/day. In elderly patients the recommended dose
for long term treatment is 7.5 mg/day.
Ankylosing spondylitis: 15 mg/day. In elderly patients the recommended dose
is 7.5 mg/day.
Do not exceed the dose of 15 mg/day. The total daily amount should be
taken as a single dose. Patients with increased risks for adverse reactions
should start treatment with 7.5 mg/day. In dialysis patients with severe renal
failure the dose should not exceed 7.5 mg/day.

For Children:
The pharmacokinetics of Meloxicam in paediatric patients under 18 years of
age have not been investigated.
CONTRAINDICATION AND PRECAUTION
Meloxicam is contraindicated to patients hypersensitive to this drug.
Meloxicam should not be given to patients who have developed signs of
asthma, nasal polyps, angioneurotic oedema or urticaria following the
administration of aspirin or NSAIDs. Meloxicam is contraindicated to
patients with active peptic ulcer during the last six months or a history of
recurrent peptic ulcer disease, severe hepatic failure,
non-dialysed severe renal failure, gastrointestinal bleeding, cerebrovascular
bleeding or other bleeding disorders.
SIDE EFFECT
Nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may
occur. Ulcers or gastrointestinal bleeding may rarely occur. Skin rash, or
urticaria may occur in some individuals. Oedema of the lower limbs may
occur during treatment. Onset of an asthma attack has been reported in
certain individuals allergic to aspirin or to other NSAIDs. Headache, vertigo
or drowsiness may occur.
DRUG INTERACTION
Other NSAIDs, including high doses of salicylates: Administration of several
NSAIDs together may increase the risk of ulcers and of gastrointestinal
bleeding, via a synergistic effect.
Oral anticoagulants, heparin and ticlopidine: Increased risk of bleeding via
inhibition of platelet function and damage to the gastroduodenal mucosa.
Careful monitoring of the effects of anticoagulants is thus essential if it
proves impossible to avoid such combined prescription.
Lithium: NSAIDs increase blood lithium levels, which may then reach toxic
values.
Methotrexate: NSAIDs may accentuate the haematologic toxicity of
methotrexate.
Intrauterine contraceptive devices: NSAIDs appear to decrease the efficacy
of intrauterine contraceptive devices.

USE IN PREGNANCY AND LACTATION
Pregnancy: It is advisable to avoid the administration of Meloxicam during
pregnancy.
Lactation: It is unknown whether Meloxicam passes into mother’s milk.
Meloxicam should not be given to nursing mothers

Sold out